BenevolentAI: Appointment of Adviser
2024年7月4日 - 2:00PM
ビジネスワイヤ(英語)
BenevolentAI ("BenevolentAI" or the "Company") (Euronext
Amsterdam: BAI), a leader in applying advanced AI to accelerate
biopharma drug discovery, announces the appointment of Deutsche
Numis as the Company’s Financial and Capital Markets Adviser, with
immediate effect.
Kenneth Mulvany, Deputy Chair of BenevolentAI,
commented:
“We are pleased to appoint Deutsche Numis as our UK and
pan-European corporate broker. We look forward to working with
their team to maximise our capital markets strategy and realise the
true value in BenevolentAI.”
Category: non-regulatory
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our
proprietary and validated Benevolent Platform™ that integrates AI
and science to uncover new biology, predict novel targets and
develop first-in-class or best-in-class drugs for complex diseases.
By applying proprietary advanced AI tools, in combination with
in-house scientific expertise and wet-lab facilities, BenevolentAI
is well-positioned to identify and accelerate novel drug
discovery.
The Company’s business model presents multiple routes for value
creation including discovery collaborations with pharma companies
like AstraZeneca and Merck and advancing in-house pipelines to
inflection points. Headquartered in London, with wet labs in
Cambridge (UK), BenevolentAI is at the forefront of reshaping the
future of drug discovery and delivering innovative medicines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240703455107/en/
BenevolentAI:
Investors Dr Joerg Moeller – Chief Executive
Officer investors@benevolent.ai
Media James Osborn – Communications Lead
press@benevolent.ai
FTI Consulting: Ben Atwell / Simon Conway / Victoria
Foster Mitchell T: +44 203 727 1000
BenevolentAI@fticonsulting.com
Deutsche Numis: Freddie Barnfield / Euan Brown / Peter
Davis / Michael Palser T: +44 207 260 1000
dbnumis_BenevolentAI@dbnumis.com